

# Susan E Yost

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6903672/publications.pdf>

Version: 2024-02-01

33  
papers

786  
citations

567281

15  
h-index

552781

26  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1197  
citing authors

#	ARTICLE	IF	CITATIONS
1	Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients. <i>JCI Insight</i> , 2019, 4, .	5.0	83
2	Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges. <i>Cancers</i> , 2020, 12, 1404.	3.7	78
3	Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts. <i>Clinical Cancer Research</i> , 2020, 26, 657-668.	7.0	70
4	CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer. <i>BMC Cancer</i> , 2019, 19, 96.	2.6	60
5	A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. <i>Oncologist</i> , 2021, 26, 99-e217.	3.7	49
6	Cancer-cell-secreted extracellular vesicles suppress insulin secretion through miR-122 to impair systemic glucose homeostasis and contribute to tumour growth. <i>Nature Cell Biology</i> , 2022, 24, 954-967.	10.3	35
7	Effect of physico-chemical modification on the immunogenicity of Haemophilus influenzae type b oligosaccharide- $\alpha$ -CRM197 conjugate vaccines. <i>Vaccine</i> , 2001, 19, 3189-3200.	3.8	34
8	Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer. <i>European Journal of Cancer</i> , 2021, 154, 11-20.	2.8	34
9	Interaction of Haemophilus influenzae type b conjugate vaccines with diphtheria-tetanus-pertussis vaccine in control tests. <i>Vaccine</i> , 1994, 12, 1460-1466.	3.8	29
10	Mutation and immune profiling of metaplastic breast cancer: Correlation with survival. <i>PLoS ONE</i> , 2019, 14, e0224726.	2.5	29
11	Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer. <i>Oncologist</i> , 2021, 26, e382-e393.	3.7	27
12	Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer. <i>Cells</i> , 2019, 8, 1010.	4.1	25
13	Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 119.	5.0	21
14	Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer. <i>Scientific Reports</i> , 2019, 9, 7509.	3.3	21
15	Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis. <i>PLoS ONE</i> , 2020, 15, e0229955.	2.5	20
16	Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes. <i>BMC Cancer</i> , 2019, 19, 881.	2.6	19
17	Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer. , 2021, 9, e002084.		16
18	Analysis of Gut Microbiome Using Explainable Machine Learning Predicts Risk of Diarrhea Associated With Tyrosine Kinase Inhibitor Neratinib: A Pilot Study. <i>Frontiers in Oncology</i> , 2021, 11, 604584.	2.8	16

#	ARTICLE	IF	CITATIONS
19	Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome. <i>Npj Breast Cancer</i> , 2021, 7, 84.	5.2	16
20	Combination of DTP and Haemophilus influenzae Type b Conjugate Vaccines can Affect Laboratory Evaluation of Potency and Immunogenicity. <i>Biologicals</i> , 1994, 22, 339-345.	1.4	15
21	Genomic and epigenomic <i>BRCA</i> alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	15
22	Genomic mutation-driven metastatic breast cancer therapy: a single center experience. <i>Oncotarget</i> , 2017, 8, 26414-26423.	1.8	12
23	Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer. <i>Cancer Immunology Research</i> , 2022, 10, 829-843.	3.4	12
24	Physics approaches to the spatial distribution of immune cells in tumors. <i>Reports on Progress in Physics</i> , 2021, 84, 022601.	20.1	10
25	Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. <i>Cancers</i> , 2021, 13, 2776.	3.7	9
26	Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 101.	5.0	7
27	Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 582185.	2.8	5
28	Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer. <i>Cancers</i> , 2022, 14, 3159.	3.7	5
29	Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer. <i>Oncologist</i> , 2017, 22, 1189-1196.	3.7	3
30	Occupancy and Fractal Dimension Analyses of the Spatial Distribution of Cytotoxic (CD8+) T Cells Infiltrating the Tumor Microenvironment in Triple Negative Breast Cancer. <i>Biophysical Reviews and Letters</i> , 2020, 15, 83-98.	0.8	3
31	Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 752-758.	1.0	3
32	Metabolic syndrome risk components and mortality after triple-negative breast cancer diagnosis in postmenopausal women in the Women's Health Initiative. <i>Cancer</i> , 2021, 127, 1658-1667.	4.1	2
33	Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations. <i>Future Science OA</i> , 2021, 7, FSO662.	1.9	1